Lin Chang1, Jifeng Zhang1, Yu-Hua Tseng1, Chang-Qing Xie1, Jacob Ilany1, Jens C Brüning1, Zhongcui Sun1, Xiaojun Zhu1, Taixing Cui1, Keith A Youker1, Qinglin Yang1, Sharlene M Day1, C Ronald Kahn1, Y Eugene Chen1. 1. Cardiovascular Center (L.C., J.Z., C.-Q.X., T.C., S.M.D., Y.E.C.), Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Mich; Joslin Diabetes Center (Y.-H.T., J.I., J.C.B., C.R.K.), Harvard Medical School, Boston, Mass; Institute of Molecular Medicine (Z.S., X.Z.), Peking University, Beijing, People's Republic of China; Department of Cardiology (K.A.Y.), The Methodist Hospital Research Institute, Houston, Tex; and Cardiovascular Research Institute (Q.Y.), Morehouse School of Medicine, Atlanta, Ga.
Abstract
BACKGROUND: Rad (Ras associated with diabetes) GTPase is the prototypic member of a subfamily of Ras-related small G proteins. The aim of the present study was to define whether Rad plays an important role in mediating cardiac hypertrophy. METHODS AND RESULTS: We document for the first time that levels of Rad mRNA and protein were decreased significantly in human failing hearts (n=10) compared with normal hearts (n=3; P<0.01). Similarly, Rad expression was decreased significantly in cardiac hypertrophy induced by pressure overload and in cultured cardiomyocytes with hypertrophy induced by 10 micromol/L phenylephrine. Gain and loss of Rad function in cardiomyocytes significantly inhibited and increased phenylephrine-induced hypertrophy, respectively. In addition, activation of calcium-calmodulin-dependent kinase II (CaMKII), a strong inducer of cardiac hypertrophy, was significantly inhibited by Rad overexpression. Conversely, downregulation of CaMKIIdelta by RNA interference technology attenuated the phenylephrine-induced hypertrophic response in cardiomyocytes in which Rad was also knocked down. To further elucidate the potential role of Rad in vivo, we generated Rad-deficient mice and demonstrated that they were more susceptible to cardiac hypertrophy associated with increased CaMKII phosphorylation than wild-type littermate controls. CONCLUSIONS: The present data document for the first time that Rad is a novel mediator that inhibits cardiac hypertrophy through the CaMKII pathway. The present study will have significant implications for understanding the mechanisms of cardiac hypertrophy and setting the basis for the development of new strategies for treatment of cardiac hypertrophy.
BACKGROUND:Rad (Ras associated with diabetes) GTPase is the prototypic member of a subfamily of Ras-related small G proteins. The aim of the present study was to define whether Rad plays an important role in mediating cardiac hypertrophy. METHODS AND RESULTS: We document for the first time that levels of Rad mRNA and protein were decreased significantly in human failing hearts (n=10) compared with normal hearts (n=3; P<0.01). Similarly, Rad expression was decreased significantly in cardiac hypertrophy induced by pressure overload and in cultured cardiomyocytes with hypertrophy induced by 10 micromol/L phenylephrine. Gain and loss of Rad function in cardiomyocytes significantly inhibited and increased phenylephrine-induced hypertrophy, respectively. In addition, activation of calcium-calmodulin-dependent kinase II (CaMKII), a strong inducer of cardiac hypertrophy, was significantly inhibited by Rad overexpression. Conversely, downregulation of CaMKIIdelta by RNA interference technology attenuated the phenylephrine-induced hypertrophic response in cardiomyocytes in which Rad was also knocked down. To further elucidate the potential role of Rad in vivo, we generated Rad-deficient mice and demonstrated that they were more susceptible to cardiac hypertrophy associated with increased CaMKII phosphorylation than wild-type littermate controls. CONCLUSIONS: The present data document for the first time that Rad is a novel mediator that inhibits cardiac hypertrophy through the CaMKII pathway. The present study will have significant implications for understanding the mechanisms of cardiac hypertrophy and setting the basis for the development of new strategies for treatment of cardiac hypertrophy.
Authors: Minoru Satoh; Hisakazu Ogita; Kyosuke Takeshita; Yasushi Mukai; David J Kwiatkowski; James K Liao Journal: Proc Natl Acad Sci U S A Date: 2006-05-01 Impact factor: 11.205
Authors: Chunyan Pang; Shawn M Crump; Ling Jin; Robert N Correll; Brian S Finlin; Jonathan Satin; Douglas A Andres Journal: Channels (Austin) Date: 2010-05-01 Impact factor: 2.581
Authors: Janet R Manning; Catherine N Withers; Bryana Levitan; Jeffrey D Smith; Douglas A Andres; Jonathan Satin Journal: Am J Physiol Heart Circ Physiol Date: 2015-09-14 Impact factor: 4.733
Authors: Catherine N Withers; Drew M Brown; Innocent Byiringiro; Matthew R Allen; Keith W Condon; Jonathan Satin; Douglas A Andres Journal: Bone Date: 2017-07-18 Impact factor: 4.398
Authors: Brooke M Ahern; Bryana M Levitan; Sudhakar Veeranki; Mihir Shah; Nemat Ali; Andrea Sebastian; Wen Su; Ming C Gong; Jiayang Li; Julian E Stelzer; Douglas A Andres; Jonathan Satin Journal: J Biol Chem Date: 2019-05-30 Impact factor: 5.157